title: Tendosynovial sarcoma. Clinicopathologic features, treatment, and prognosis.
abstract: BACKGROUND
  Clinicopathologic features, treatment, and results are reported for 95 tendosynovial sarcomas identified from a prospective sarcoma data base established at Memorial Sloan-Kettering Cancer Center (MSKCC) in 1982.
  
  
  METHODS
  Eighty-five patients had definitive treatment of the primary tumor at MSKCC: Epithelial sarcomas were excluded.
  
  
  RESULTS
  The local recurrence rate was 18%. Survival rates were not influenced by either the method of local treatment or the use of chemotherapy. The overall actuarial survival rate was 59% at 5 years (median, 92 months). For 25 patients who had resection of pulmonary metastases, the 5-year actuarial survival rate was 43% (median, 22 months) from the time of first thoracotomy. Sex, age, tumor site, and histologic subtype (monophasic versus biphasic) were not significant predictors of survival rates. Regional lymph node metastasis occurred in 3%. The incidence of distant metastasis was 49%, with an associated 5-year survival rate of 31% (median, 33 months). Tumor size was a highly significant prognostic feature, with 5-year survival rates of 86% for patients with tumors smaller than 5 cm and 22% for those with tumors larger than 10 cm (P less than 0.00001).
  
  
  CONCLUSIONS
  Improvement of treatment results for tendosynovial sarcoma will require effective new systemic adjuvant therapeutic strategies.
authors.affiliation: Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
authors.forename: J T
authors.initials: JT
authors.lastname: Brodsky
authors.forename: M E
authors.initials: ME
authors.lastname: Burt
authors.forename: S I
authors.initials: SI
authors.lastname: Hajdu
authors.forename: E S
authors.initials: ES
authors.lastname: Casper
authors.forename: M F
authors.initials: MF
authors.lastname: Brennan
mesh_terms: D000206:Actuarial Analysis; D000293:Adolescent; D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000473:pathology / Q000628:therapy; D011379:Prognosis; D011446:Prospective Studies; D013584:Sarcoma, Synovial / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D012983:Soft Tissue Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D015996:Survival Rate